CTLA4 and lymphedema: In agreement with the preclinical results obtained, anti-CTLA4 therapy downregulated all key processes linked to lymphedema, namely fibrosis, epithelium degeneration and edema (Fig. 5G), further strengthening the therapeutic effect of the examined agent.